Brought to you by 
University College London, Eisai collaborate on neurodegenerative disease candidates
07 Jul 2016
Executive Summary
University College London (UCL) and Eisai Co. Ltd. have agreed to discover and develop drug candidates for Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. Eisai will have marketing rights to resulting therapeutics.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
University College London, Eisai collaborate on neurodegenerative disease candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice